Jubilant Ingrevia Ltd
Jubilant Ingrevia Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Expecting steady growth across segments with pipeline of 100+ active opportunities and 50+ products under development. Expectation to achieve INR1,200 crore peak annualized revenue from 10+ new CDMO molecules in 2-3 years, including a major $300 million (INR500 crore annual) contract starting early next year.
From Jubilant Ingrevia Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Expecting steady growth across segments with pipeline of 100+ active opportunities and 50+ products under development.
- Anticipate INR1,200 crore peak annual revenue from 10+ new CDMO and Fine Chemical molecules, contributing revenue from FY '26 and ramping up over 2-3 years.
- FY '26 includes launch of 18 new products aligned with market needs.
- Nutrition segment volume growth seen in vitamin B3 and B4, with strong traction in cosmetic grade sales.
- Anti-dumping duties on China creating new export opportunities, especially for choline chloride in Europe.
- Capacity expansions, including new multipurpose plant at Gajraula and semiconductor R&D facility, planned to support growth from 2026-27 onward.
- Ongoing cost optimization and lean savings program supporting margin expansion amid pricing pressures.
2 more points from Jubilant Ingrevia Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Ingrevia Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR59 crore capex incurred in the quarter, primarily towards the upcoming CDMO Agro plant at Bharuch and new multipurpose facility in Gajraula.
- Planned investment of approximately INR600 crore in FY '26, funded largely through internal accruals.
- Commissioning of $300 million Agro-Innovator CDMO project expected by Q4 FY '26.
- New boiler commissioning at Bharuch scheduled for Q3 FY '26 to enhance operational efficiency.
- Debottlenecking capacity in existing plants by 15-20% to support new CDMO and Fine Chemical volumes.
- Groundbreaking of new multipurpose plant at Gajraula to add flexibility and capacity in CDMO portfolio.
2 more points from Jubilant Ingrevia Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Ingrevia Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has expanded its opportunity funnel to over 100+ active opportunities, up from 70 in Q1, indicating a healthy and growing orderbook.
- There are 10 molecules already signed in the CDMO business, with one molecule already supplied and others in various stages of supply ramp-up.
- Another 10+ opportunities are in advanced stages of discussion, expected to convert into confirmed orders in coming quarters.
- For the new CDMO molecules, revenues typically ramp up from 15-20% in Year 1, to 40-60% in Year 2, and reach peak (80-100%) by Year 3.
2 more points from Jubilant Ingrevia Ltd's call on order book
Create a free account to keep reading this call
Jubilant Ingrevia Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹111 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Ingrevia Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Gujarat Alkalies (Q2 FY26)
2,136.64 Crores (Page 21). Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q2 FY26 investor presentation — and how it ranks against
- Dynemic Products Ltd (Q2 FY26)
Quarterly revenue for Q2 FY 25-26: ₹8,935 lakhs (Page 12, 10, 5) . Key investor presentation takeaways from Dynemic Products's Q2 FY26 investor presentation — a
- Platinum Industries Ltd (Q2 FY26)
Q2FY26 Revenue from Operations (Consolidated): INR 983.8 Mn, down 1% YoY from INR 996.4 Mn in Q2FY25. Key investor presentation takeaways from Platinum Industri
- IVP Ltd (Q2 FY26)
Revenue from Operations for Q2FY26: ₹146.95 crores . Key investor presentation takeaways from IVP's Q2 FY26 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Ingrevia Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Ingrevia Ltd Q2 FY26 results?
Expecting steady growth across segments with pipeline of 100+ active opportunities and 50+ products under development. Expectation to achieve INR1,200 crore peak annualized revenue from 10+ new CDMO molecules in 2-3 years, including a major $300 million (INR500 crore annual) contract starting early next year.
What is Jubilant Ingrevia Ltd share price analysis?
Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 36.9 with a market cap of ₹11,738 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrevia Ltd planning capital expenditure?
INR59 crore capex incurred in the quarter, primarily towards the upcoming CDMO Agro plant at Bharuch and new multipurpose facility in Gajraula.
Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.